Summit Therapeutics is trading 4.05% up in pre-market at $17.98, driven by continued investor interest in positive HARMONi-2 Phase 3 results from partner Akeso.
- HARMONi-2 showed ivonescimab delivered a statistically significant overall-survival benefit versus pembrolizumab in PD-L1-positive non-small-cell lung cancer.
- UBS reiterated Buy and maintained a $33 price target on September 8, 2026, supporting bullish sentiment despite weaker broader-market futures.